Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Taxane chemotherapy is standard for castration-resistant prostate cancer (CRPC).
• The precise mechanisms by which taxanes impact the androgen receptor (AR) in CRPC remain incompletely understood.
• Identifying novel therapeutic targets and understanding treatment resistance mechanisms are critical in CRPC management.

Purpose of the Study:

• To elucidate the role of c-jun in mediating the effects of taxane chemotherapy in CRPC.
• To investigate the interaction between c-jun and the androgen receptor (AR) and its influence on treatment outcomes.
• To explore the differential effects of docetaxel and paclitaxel on CRPC cell lines and their impact on c-jun, AR, and PSA expression.

Main Methods:

• In vitro studies using LNCaP and LNb4 prostate cancer cell lines.
• Analysis of protein and mRNA levels of c-jun, AR, and PSA following treatment with docetaxel and paclitaxel.
• Investigation of c-jun phosphorylation in relation to JNK pathways.
• In vivo xenograft studies in mice treated with paclitaxel and bicalutamide.

Main Results:

• c-jun was identified as a crucial protein interacting with AR, influencing taxane therapy outcomes.
• Docetaxel and paclitaxel demonstrated distinct effects on c-jun, AR, and PSA levels in CRPC cells.
• Docetaxel-induced c-jun phosphorylation occurred independently of JNK pathways.
• Upregulation of c-jun showed potential anti-apoptotic effects, as evidenced by worse outcomes in xenograft models with paclitaxel and bicalutamide.
• An inverse regulation between PSA and AR mRNA levels was observed in docetaxel-treated LNb4 cells, also noted for KLK2.

Conclusions:

• c-jun is a critical mediator in taxane therapy for CRPC, interacting with AR to determine treatment efficacy.
• The observed anti-apoptotic role of c-jun suggests its potential as a therapeutic target.
• PSA levels may not accurately reflect AR activity in CRPC patients undergoing taxane therapy, necessitating a re-evaluation of treatment response assessment.